The Provision of Medicines in Russia: Budget, Balance and Outcome

January 13, 2017, 12:00 – 14:00, Building 5, 5th Floor, Executive Conference Room

Issues for Discussion

  • Value-based medicine is a new reality in the world.  What could those values be: health indicators, patient's condition, impact on the health system, economy and society as a whole?
  • Cost management methods - cost containment or optimization?
  • Is it possible and justified to introduce in Russia mechanisms for effective interaction between the State and business within the drug procurement process, where payment is made based on the efficacy of treatment?
  • Conditions required for the introduction of such a system: legislation, regulatory environment in public procurement, monitoring, recording and quality evaluation system


  • Vitaly Omelyanovsky
    Vitaly Omelyanovsky

    Director, Center of Healthcare Expert Evaluation and Quality Control of the Ministry of Health of the Russian Federation


  • Veronika Skvortsova
    Veronika Skvortsova

    Minister of Healthcare of the Russian Federation

  • Jane Griffiths
    Jane Griffiths

    Company Group Chairman, Janssen Pharmaceutical Companies, Johnson & Johnson

  • John Ketchum
    John Ketchum

    Senior Vice-President and Region Head, Emerging Growth Markets, Novartis Oncology

  • Frank R. Lichtenberg
    Frank R. Lichtenberg

    Professor of Business, Columbia University Graduate School of Business; Research Associate, National Bureau of Economic Research

  • Yulia Mikheeva
    Yulia Mikheeva

    Director, Social Development Department, Ministry of Economic Development of the Russian Federation

  • Marwan Akar
    Marwan Akar

    Vice-President, Managing Director, MSD Russia

  • Tatiana Bykovskaya
    Tatiana Bykovskaya

    Minister of Healthcare of the Rostov region

  • Evgeniy Shlyakhto
    Evgeniy Shlyakhto

    General Director, Almazov National Medical Research Centre